Compare AMPG & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPG | GNLX |
|---|---|---|
| Founded | 2002 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.7M | 110.4M |
| IPO Year | 2012 | 2022 |
| Metric | AMPG | GNLX |
|---|---|---|
| Price | $3.39 | $2.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 1.0M | 308.3K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.44 | 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,195,930.00 | $8,000.00 |
| Revenue This Year | $102.41 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 164.99 | N/A |
| 52 Week Low | $1.64 | $2.29 |
| 52 Week High | $10.11 | $8.54 |
| Indicator | AMPG | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 45.71 |
| Support Level | $3.20 | $2.34 |
| Resistance Level | $3.61 | $2.90 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 40.74 | 44.57 |
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. It operates in two segments: the manufacturing and engineering segment. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.